Manifestation of severe coronary heart disease after anabolic drug abuse

Clinical Cardiology

Volumn 19, Issue 2, 1996, Pages 153-155

  Mewis, C ^a   Spyridopoulos, I ^a   Kuhlkamp V ^a   Seipel, L ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

anabolic steroids; coronary heart disease; myocardial infarction; stanazolol

Indexed keywords

STANOZOLOL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROGENESIS; ATHLETE; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DRUG ABUSE; DRUG EFFECT; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MALE;

EID: 0029820622     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190216     Document Type: Article

References (13)

1. Webb OL, Laskarzewski PM, Glueck CJ: Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabolism 33, 971-975 (1984)
2. Baldo-Enzi G, Giada F, Zuliani G, Baroni L, Vitale E, Enzi G, Magnanini P, Fellin R: Lipid and apoprotein modifications in bodybuilders during and after self-administration of anabolic steroids. Metabolism 39, 203-208 (1990)
3. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, Herbert PN: Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. J Am Med Assoc 261, 1165-1168 (1989)
4. McNutt RA, Ferenchick GS, Kirlin PC, Hamlin NJ: Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol 62, 164 (1988)
5. Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ. van't Laar A, Thien T: Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med 9, 19-23 (1988)
6. Urhausen AR, Holpes R, Kindermann W: One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol 58, 633-640 (1989)
7. Taggart HM, Applebaum-Bowden D, Haffner S, Warnick GR, Cheung MC, Albers JJ, Chestnut CH, Hazzard WR: Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis Metabolism 31, 1147-1152 (1982)
8. Haffner SM, Kushwaha RS, Foster DM, Applebaum-Bowden D, Hazzard WR: Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism 32, 413-420 (1983)
9. Alen M, Rahkila P, Marniemi J: Serum lipids in power athletes self-administering testosterone and anabolic steroids. Int J Sports Med 6, 139-144 (1985)
10. Miller NE, Forde OH, Thelle DS, Mojos DS: The Tromso heart study. High density lipoprotein and coronary heart disease: A prospective case control study. Lancet 1, 965-968 (1977)
11. Melchert RB, Herron TJ, Welder AA: The effect of anabolic-androgenic steroids on primary myocardial cell cultures. Med Sci Sports Exerc 24, 206-212 (1992)
12. Fogelberg M, Bjorkhem I, Diczfalusy U, Henriksson P: Stanozolol and experimental atherosclerosis. Atherosclerotic development and blood lipids during anabolic steroid therapy of New Zealand white rabbits. Scand J Clin Lab Invest 50, 693-696 (1990)
13. Hoit BD, Gilpin EA, Henning H, Maisel AA, Dittrich H, Carlisle J, Ross J: Myocardial infarction in young patients: An analysis by age subsets. Circulation 4, 712-721 (1986)